Abstract
For immunotherapy of residual disease in patients with Philadelphia-positive leukemias, the BCR-ABL fusion regions are attractive disease-specific T-cell targets. We analyzed these regions for the prevalence of cytotoxic T lymphocyte (CTL) epitopes by an advanced reverse immunology procedure. Seventeen novel BCR-ABL fusion peptides were identified to bind efficiently to the human lymphocyte antigen (HLA)-A68, HLA-B51, HLA-B61 or HLA-Cw4 HLA class I molecules. Comprehensive enzymatic digestion analysis showed that 10 out of the 28 HLA class I binding fusion peptides were efficiently excised after their C-terminus by the proteasome, which is an essential requirement for efficient cell surface expression. Therefore, these peptides are prime vaccine candidates. The other peptides either completely lacked C-terminal liberation or were only inefficiently excised by the proteasome, rendering them inappropriate or less suitable for inclusion in a vaccine. CTL raised against the properly processed HLA-B61 epitope AEALQRPVA from the BCR-ABL e1a2 fusion region, expressed in acute lymphoblastic leukemia (ALL), specifically recognized ALL tumor cells, proving cell surface presentation of this epitope, its applicability for immunotherapy and underlining the accuracy of our epitope identification strategy. Our study provides a reliable basis for the selection of optimal peptides to be included in immunotherapeutic BCR-ABL vaccines against leukemia.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Kolb HJ, Simoes B, Schmid C . Cellular immunotherapy after allogeneic stem cell transplantation in hematologic malignancies. Curr Opin Oncol 2004; 16: 167–173.
Goulmy E . Human minor histocompatibility antigens: new concepts for marrow transplantation and adoptive immunotherapy. Immunol Rev 1997; 157: 125–140.
Gannage M, Abel M, Michallet AS, Delluc S, Lambert M, Giraudier S et al. Ex vivo characterization of multiepitopic tumor-specific CD8T cells in patients with chronic myeloid leukemia: implications for vaccine development and adoptive cellular immunotherapy. J Immunol 2005; 174: 8210–8218.
Molldrem JJ, Lee PP, Wang C, Felio K, Kantarjian HM, Champlin RE et al. Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia. Nat Med 2000; 6: 1018–1023.
Goldman JM . Chronic myeloid leukemia. Curr Opin Hematol 1997; 4: 277–285.
Melo JV . The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype. Blood 1996; 88: 2375–2384.
Kantarjian H, Sawyers C, Hochhaus A, Guilhot F, Schiffer C, Gambacorti-Passerini C et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002; 346: 645–652.
Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996; 2: 561–566.
Hughes TP, Kaeda J, Branford S, Rudzki Z, Hochhaus A, Hensley ML et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 2003; 349: 1423–1432.
Shah NP, Nicoll JM, Nagar B, Gorre ME, Paquette RL, Kuriyan J et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2002; 2: 117–125.
Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001; 293: 876–880.
Bosch GJ, Joosten AM, Kessler JH, Melief CJ, Leeksma OC . Recognition of BCR-ABL positive leukemic blasts by human CD4+ T cells elicited by primary in vitro immunization with a BCR-ABL breakpoint peptide. Blood 1996; 88: 3522–3527.
Jiang YZ, Mavroudis D, Dermime S, Hensel N, Couriel D, Molldrem J et al. Alloreactive CD4+ T lymphocytes can exert cytotoxicity to chronic myeloid leukaemia cells processing and presenting exogenous antigen. Br J Haematol 1996; 93: 606–612.
Bocchia M, Wentworth PA, Southwood S, Sidney J, McGraw K, Scheinberg DA et al. Specific binding of leukemia oncogene fusion protein peptides to HLA class I molecules. Blood 1995; 85: 2680–2684.
Greco G, Fruci D, Accapezzato D, Barnaba V, Nisini R, Alimena G et al. Two brc-abl junction peptides bind HLA-A3 molecules and allow specific induction of human cytotoxic T lymphocytes. Leukemia 1996; 10: 693–699.
Berke Z, Andersen MH, Pedersen M, Fugger L, Zeuthen J, Haurum JS . Peptides spanning the junctional region of both the abl/bcr and the bcr/abl fusion proteins bind common HLA class I molecules. Leukemia 2000; 14: 419–426.
Buzyn A, Ostankovitch M, Zerbib A, Kemula M, Connan F, Varet B et al. Peptides derived from the whole sequence of BCR-ABL bind to several class I molecules allowing specific induction of human cytotoxic T lymphocytes. Eur J Immunol 1997; 27: 2066–2072.
Barrett J, Guimaraes A, Cullis J, Goldman JM . Immunological characterization of the tumor-specific bcr/abl junction of Philadelphia chromosome positive chronic myeloid leukemia. Stem Cells 1993; 11: 104–108.
Cullis JO, Barrett AJ, Goldman JM, Lechler RI . Binding of BCR/ABL junctional peptides to major histocompatibility complex (MHC) class I molecules: studies in antigen-processing defective cell lines. Leukemia 1994; 8: 165–170.
Yotnda P, Firat H, Garcia-Pons F, Garcia Z, Gourru G, Vernant JP et al. Cytotoxic T cell response against the chimeric p210 BCR-ABL protein in patients with chronic myelogenous leukemia. J Clin Invest 1998; 101: 2290–2296.
Bocchia M, Korontsvit T, Xu Q, Mackinnon S, Yang SY, Sette A et al. Specific human cellular immunity to bcr-abl oncogene-derived peptides. Blood 1996; 87: 3587–3592.
Norbury LC, Clark RE, Christmas SE . b3a2 BCR-ABL fusion peptides as targets for cytotoxic T cells in chronic myeloid leukaemia. Br J Haematol 2000; 109: 616–621.
Papadopoulos KP, Suciu-Foca N, Hesdorffer CS, Tugulea S, Maffei A, Harris PE . Naturally processed tissue and differentiation stage specific autologous peptides bound by HLA class I and II molecules of chronic myeloid leukemia blasts. Blood 1997; 90: 4938–4946.
Clark RE, Dodi IA, Hill SC, Lill JR, Aubert G, Macintyre AR et al. Direct evidence that leukemic cells present HLA-associated immunogenic peptides derived from the BCR-ABL b3a2 fusion protein. Blood 2001; 98: 2887–2893.
Cathcart K, Pinilla-Ibarz J, Korontsvit T, Schwartz J, Zakhaleva V, Papadopoulus EB et al. A multivalent bcr-abl fusion peptide vaccination trial in patients with chronic myeloid leukemia. Blood 2003; 103: 1037.
Pinilla-Ibarz J, Cathcart K, Korontsvit T, Soignet S, Bocchia M, Caggiano J et al. Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpoint fusion peptides generates specific immune responses. Blood 2000; 95: 1781–1787.
Bocchia M, Gentili S, Abruzzese E, Fanelli A, Iuliano F, Tabilio A et al. Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre observational trial. Lancet 2005; 365: 657–662.
Kessler JH, Beekman NJ, Bres-Vloemans SA, Verdijk P, van Veelen PA, Kloosterman-Joosten AM et al. Efficient identification of novel HLA-A(*)0201-presented cytotoxic T lymphocyte epitopes in the widely expressed tumor antigen PRAME by proteasome-mediated digestion analysis. J Exp Med 2001; 193: 73–88.
Beekman NJ, van Veelen PA, van Hall T, Neisig A, Sijts A, Camps M et al. Abrogation of CTL epitope processing by single amino acid substitution flanking the C-terminal proteasome cleavage site. J Immunol 2000; 164: 1898–1905.
Craiu A, Akopian T, Goldberg A, Rock KL . Two distinct proteolytic processes in the generation of a major histocompatibility complex class I-presented peptide. Proc Natl Acad Sci USA 1997; 94: 10850–10855.
Snyder HL, Bacik I, Yewdell JW, Behrens TW, Bennink JR . Promiscuous liberation of MHC-class I-binding peptides from the C termini of membrane and soluble proteins in the secretory pathway. Eur J Immunol 1998; 28: 1339–1346.
Mo XY, Cascio P, Lemerise K, Goldberg AL, Rock K . Distinct proteolytic processes generate the C and N termini of MHC class I-binding peptides. J Immunol 1999; 163: 5851–5859.
Kloetzel PM, Ossendorp F . Proteasome and peptidase function in MHC-class-I-mediated antigen presentation. Curr Opin Immunol 2004; 16: 76–81.
Saveanu L, Carroll O, Hassainya Y, van Endert P . Complexity, contradictions, and conundrums: studying post-proteasomal proteolysis in HLA class I antigen presentation. Immunol Rev 2005; 207: 42–59.
Yewdell JW, Bennink JR . Immunodominance in major histocompatibility complex class I-restricted T lymphocyte responses. Annu Rev Immunol 1999; 17: 51–88.
Ayyoub M, Stevanovic S, Sahin U, Guillaume P, Servis C, Rimoldi D et al. Proteasome-assisted identification of a SSX-2-derived epitope recognized by tumor-reactive CTL infiltrating metastatic melanoma. J Immunol 2002; 168: 1717–1722.
Hassainya Y, Garcia-Pons F, Kratzer R, Lindo V, Greer F, Lemonnier FA et al. Identification of naturally processed HLA-A2--restricted proinsulin epitopes by reverse immunology. Diabetes 2005; 54: 2053–2059.
Pinkse GG, Tysma OH, Bergen CA, Kester MG, Ossendorp F, van Veelen PA et al. Autoreactive CD8 T cells associated with beta cell destruction in type 1 diabetes. Proc Natl Acad Sci USA 2005; 102: 18425–18430.
Sekimata M, Hayashi H, Nakayama S, Kano K, Takiguchi M . Serological demonstration of HLA-Bw4/Bw6 epitopes on hybrid molecules between HLA-B35 and HLA-B51. Immunogenetics 1989; 30: 229–231.
Parker KC, Bednarek MA, Coligan JE . Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. J Immunol 1994; 152: 163–175.
Rammensee H, Bachmann J, Emmerich NP, Bachor OA, Stevanovic S . SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics 1999; 50: 213–219.
D'Amaro J, Houbiers JG, Drijfhout JW, Brandt RMP, Schipper R, Bavinck JN et al. A computer program for predicting possible cytotoxic T lymphocyte epitopes based on HLA class I peptide-binding motifs. Hum Immunol 1995; 43: 13–18.
Kessler JH, Mommaas B, Mutis T, Huijbers I, Vissers D, Benckhuijsen WE et al. Competition-based cellular peptide binding assays for 13 prevalent HLA class I alleles using fluorescein-labeled synthetic peptides. Hum Immunol 2003; 64: 245–255.
van der Burg SH, Ras E, Drijfhout JW, Benckhuijsen WE, Bremers AJ, Melief CJM et al. An HLA class I peptide-binding assay based on competition for binding to class I molecules on intact human B cells. Identification of conserved HIV-1 polymerase peptides binding to HLA-A*0301. Hum Immunol 1995; 44: 189–198.
Falk K, Rotzschke O, Takiguchi M, Gnau V, Stevanovic S, Jung G et al. Peptide motifs of HLA-B51, -B52 and -B78 molecules, and implications for Behcet's disease. Int Immunol 1995; 7: 223–228.
Johnson RP, Trocha A, Buchanan TM, Walker BD . Recognition of a highly conserved region of human immunodeficiency virus type 1 gp120 by an HLA-Cw4-restricted cytotoxic T-lymphocyte clone. J Virol 1993; 67: 438–445.
van der Burg SH, Visseren MJ, Brandt RM, Kast WM, Melief CJ . Immunogenicity of peptides bound to MHC class I molecules depends on the MHC-peptide complex stability. J Immunol 1996; 156: 3308–3314.
Groettrup M, Ruppert T, Kuehn L, Seeger M, Standera S, Koszinowski U et al. The interferon-inducible 11S regulator (PA28) and the LMP2/LMP7 subunits govern the peptide production by the 20S proteasome in vitro. J Biol Chem 1995; 270: 23808–23815.
Frisan T, Levitsky V, Polack A, Masucci MG . Phenotype-dependent differences in proteasome subunit composition and cleavage specificity in B cell lines. J Immunol 1998; 160: 3281–3289.
Macagno A, Gilliet M, Sallusto F, Lanzavecchia A, Nestle FO, Groettrup M . Dendritic cells up-regulate immunoproteasomes and the proteasome regulator PA28 during maturation. Eur J Immunol 1999; 29: 4037–4042.
Fikes JD, Sette A . Design of multi-epitope, analogue-based cancer vaccines. Expert Opin Biol Ther 2003; 3: 985–993.
Kopp F, Hendil KB, Dahlmann B, Kristensen P, Sobek A, Uerkvitz W . Subunit arrangement in the human 20s proteasome. Proc Natl Acad Sci USA 1997; 94: 2939–2944.
Falk K, Rotzschke O, Takiguchi M, Gnau V, Stevanovic S, Jung G et al. Peptide motifs of HLA-B58, B60, B61, and B62 molecules. Immunogenetics 1995; 41: 165–168.
Dick LR, Aldrich C, Jameson SC, Moomaw CR, Pramanik BC, Doyle CK et al. Proteolytic processing of ovalbumin and beta-galactosidase by the proteasome to a yield antigenic peptides. J Immunol 1994; 152: 3884–3894.
Ossendorp F, Eggers M, Neisig A, Ruppert T, Groettrup M, Sijts A et al. A single residue exchange within a viral CTL epitope alters proteasome- mediated degradation resulting in lack of antigen presentation. Immunity 1996; 5: 115–124.
Eggers M, Boes-Fabian B, Ruppert T, Kloetzel PM, Koszinowski UH . The cleavage preference of the proteasome governs the yield of antigenic peptides. J Exp Med 1995; 182: 1865–1870.
Niedermann G, Butz S, Ihlenfeldt HG, Grimm R, Lucchiari M, Hoschutzky H et al. Contribution of proteasome-mediated proteolysis to the hierarchy of epitopes presented by major histocompatibility complex class I molecules. Immunity 1995; 2: 289–299.
Mommaas B, Kamp J, Drijfhout JW, Beekman N, Ossendorp F, van Veelen P et al. Identification of a novel HLA-B60-restricted T cell epitope of the minor histocompatibility antigen HA-1 locus. J Immunol 2002; 169: 3131–3136.
Kuckelkorn U, Ruppert T, Strehl B, Jungblut PR, Zimny-Arndt U, Lamer S et al. Link between organ-specific antigen processing by 20S proteasomes and CD8(+) T cell-mediated autoimmunity. J Exp Med 2002; 195: 983–990.
Toes RE, Nussbaum AK, Degermann S, Schirle M, Emmerich NP, Kraft M et al. Discrete cleavage motifs of constitutive and immunoproteasomes revealed by quantitative analysis of cleavage products. J Exp Med 2001; 194: 1–12.
Kuckelkorn U, Frentzel S, Kraft R, Kostka S, Groettrup M, Kloetzel PM . Incorporation of major histocompatibility complex--encoded subunits LMP2 and LMP7 changes the quality of the 20S proteasome polypeptide processing products independent of interferon-gamma. Eur J Immunol 1995; 25: 2605–2611.
Meidenbauer N, Zippelius A, Pittet MJ, Laumer M, Vogl S, Heymann J et al. High frequency of functionally active Melan-a-specific T cells in a patient with progressive immunoproteasome-deficient melanoma. Cancer Res 2004; 64: 6319–6326.
Momburg F, Roelse J, Hammerling GJ, Neefjes JJ . Peptide size selection by the major histocompatibility complex-encoded peptide transporter. J Exp Med 1994; 179: 1613–1623.
Rock KL, York IA, Goldberg AL . Post-proteasomal antigen processing for major histocompatibility complex class I presentation. Nat Immunol 2004; 5: 670–677.
Seifert U, Maranon C, Shmueli A, Desoutter JF, Wesoloski L, Janek K et al. An essential role for tripeptidyl peptidase in the generation of an MHC class I epitope. Nat Immunol 2003; 4: 375.
Sykulev Y, Joo M, Vturina I, Tsomides TJ, Eisen HN . Evidence that a single peptide-MHC complex on a target cell can elicit a cytolytic T cell response. Immunity 1996; 4: 565–571.
Valitutti S, Muller S, Dessing M, Lanzavecchia A . Different responses are elicited in cytotoxic T lymphocytes by different levels of T cell receptor occupancy. J Exp Med 1996; 183: 1917–1921.
Faroudi M, Utzny C, Salio M, Cerundolo V, Guiraud M, Muller S et al. Lytic versus stimulatory synapse in cytotoxic T lymphocyte/target cell interaction: manifestation of a dual activation threshold. Proc Natl Acad Sci USA 2003; 100: 14145–14150.
Hudrisier D, Riond J, Garidou L, Duthoit C, Joly E . T cell activation correlates with an increased proportion of antigen among the materials acquired from target cells. Eur J Immunol 2005; 35: 2284–2294.
Sykulev Y, Cohen RJ, Eisen HN . The law of mass action governs antigen-stimulated cytolytic activity of CD8+ cytotoxic T lymphocytes. Proc Natl Acad Sci USA 1995; 92: 11990–11992.
Pinilla-Ibarz J, Korontsvit T, Zakhaleva V, Roberts W, Scheinberg DA . Synthetic peptide analogs derived from bcr/abl fusion proteins and the induction of heteroclitic human T-cell responses. Haematologica 2005; 90: 1324–1332.
Sun JY, Senitzer D, Forman SJ, Chatterjee S, Wong Jr KK . Identification of new MHC-restriction elements for presentation of the p210(BCR-ABL) fusion region to human cytotoxic T lymphocytes. Cancer Immunol Immunother 2003; 52: 761–770.
Posthuma EF, Falkenburg JH, Apperley JF, Gratwohl A, Roosnek E, Hertenstein B et al. HLA-B8 and HLA-A3 coexpressed with HLA-B8 are associated with a reduced risk of the development of chronic myeloid leukemia. The Chronic Leukemia Working Party of the EBMT. Blood 1999; 93: 3863–3865.
Mundhada S, Luthra R, Cano P . Association of HLA Class I and Class II genes with bcr-abl transcripts in leukemia patients with t(9;22) (q34;q11). BMC Cancer 2004; 4: 25.
Acknowledgements
We thank Dr M Groettrup for kindly providing antibodies of the immunoproteasome subunits, Dr KB Hendil for the antibodies to the constitutive proteasome subunits and Dr M Takiguchi for providing the C1R-B51 cell line. This work was supported by Grant UL-1994-870 from the Dutch Cancer Society (Amsterdam, The Netherlands). Furthermore, PvV and AdR are supported by the Centre for Medical Systems Biology (a center of excellence approved by the Netherlands Genomics Initiative).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kessler, J., Bres-Vloemans, S., van Veelen, P. et al. BCR-ABL fusion regions as a source of multiple leukemia-specific CD8+ T-cell epitopes. Leukemia 20, 1738–1750 (2006). https://doi.org/10.1038/sj.leu.2404354
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2404354
Keywords
This article is cited by
-
The oncogenic fusion protein DNAJB1-PRKACA can be specifically targeted by peptide-based immunotherapy in fibrolamellar hepatocellular carcinoma
Nature Communications (2022)
-
Introduction of neutralizing immunogenicity index to the rational design of MERS coronavirus subunit vaccines
Nature Communications (2016)
-
Immunology and Immunotherapy of Chronic Myeloid Leukemia
Current Hematologic Malignancy Reports (2014)
-
The role of peptide and DNA vaccines in myeloid leukemia immunotherapy
Cancer Cell International (2013)
-
BCR/ABL-specific CD8+ T cells can be detected from CML patients, but are only expanded from healthy donors
Cancer Immunology, Immunotherapy (2009)